LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Atidarymo kaina

27.94 -2.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.94

Max

29.43

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+126.46% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	32M 1.5B
Ankstesnė atidarymo kaina	30.08
Ankstesnė uždarymo kaina	27.94

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-04 21:51; UTC

Pagrindinės rinkos jėgos

Merlin Shares Rally After Defense Department's Design Review Wraps

2026-06-04 23:46; UTC

Rinkos pokalbiai

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026-06-04 23:44; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-06-04 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026-06-04 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia to Enter Trading Halt

2026-06-04 23:34; UTC

Rinkos pokalbiai

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-04 23:08; UTC

Rinkos pokalbiai

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026-06-04 22:41; UTC

Rinkos pokalbiai

Australia Shares Set to Rise at the Open -- Market Talk

2026-06-04 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 20:44; UTC

Įsigijimai, susijungimai, perėmimai

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026-06-04 20:16; UTC

Rinkos pokalbiai

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026-06-04 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026-06-04 19:46; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026-06-04 19:38; UTC

Rinkos pokalbiai

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026-06-04 19:30; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026-06-04 18:47; UTC

Įsigijimai, susijungimai, perėmimai

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026-06-04 18:38; UTC

Uždarbis

Money Quote: Tech Weakness in Context -- WSJ

2026-06-04 18:24; UTC

Uždarbis

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 17:09; UTC

Rinkos pokalbiai

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026-06-04 16:58; UTC

Uždarbis

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 16:46; UTC

Rinkos pokalbiai

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026-06-04 16:38; UTC

Uždarbis

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026-06-04 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-04 16:13; UTC

Rinkos pokalbiai

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026-06-04 16:11; UTC

Rinkos pokalbiai

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026-06-04 15:56; UTC

Rinkos pokalbiai

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

126.46% į viršų

12 mėnesių prognozė

Vidutinis 65.13 USD 126.46%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.